Knight Therapeutics’ (OTCMKTS:KHTRF) Buy Rating Reiterated at Raymond James

Knight Therapeutics (OTCMKTS:KHTRF)‘s stock had its “buy” rating reissued by analysts at Raymond James in a research note issued on Wednesday, January 16th.

Shares of OTCMKTS:KHTRF remained flat at $$6.02 during mid-day trading on Wednesday. Knight Therapeutics has a one year low of $5.62 and a one year high of $6.72.

About Knight Therapeutics

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

See Also: Guidelines for Successful Channel Trading

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Leave a Reply